Flanagan, Eoin P. http://orcid.org/0000-0002-6661-2910
Article History
Received: 26 January 2021
Revised: 13 April 2021
Accepted: 16 April 2021
First Online: 27 April 2021
Declarations
:
: The author states that there is no conflict of interest.
: Dr. Flanagan is a site principal investigator in a randomized placebo-controlled clinical trial of Inebilizumab (A CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. He receives no personal compensation and just receives reimbursement for the research activities related to the trial.